Terms ending in 2034
Every in-force patent on Biogen Ma Inc.'s record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,138,291 | Factor VIII Complex with Xten and Von Willebrand Factor Protein, and Uses Thereof In force · High confidence | Bioverativ Therapeutics Inc. | In force | High confidence | |
| US 11,370,827 | Chimeric Factor VIII Polypeptides and Uses Thereof In force · High confidence | Bioverativ Therapeutics Inc. | In force | High confidence | |
| US 9,926,559 | Compositions and Methods for Modulation of SMN2 Splicing in a Subject In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 9,765,016 | S1P Modulating Agents In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 9,506,867 | Spectroscopic Analysis of Nutrient Materials for Use in a Cell Culture Process In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 9,617,282 | Macrocyclic Compounds as IRAK4 Inhibitors for the Treatment of Inflammatory Diseases In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 12,371,747 | Methods of Reducing Immunogenicity Against Factor VIII in Individuals Undergoing Factor VIII Therapy In force · High confidence | Bioverativ Therapeutics Inc. | In force | High confidence | |
| US 9,902,775 | Anti-Blood Dendritic Cell Antigen 2 Antibodies And Uses Thereof In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 10,119,976 | Method of Assessing Risk of PML In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 10,677,803 | Method of Assessing Risk of PML In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| 30 more term ends in 2034 · Pro | |||||
10 of 40 patents shown. Soonest term end first, then patent number.
Pro members see all 40.
24 of these are in force and held by Biogen Ma Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.